Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 4/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.43 |
| ▸ | PGR | P06401 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426743 | 0.82 | MMP12 (0.57) | MMP12PARP1PDE3BPDE3ANR3C2 | |
| SCHEMBL30905978 | 0.82 | MMP12 (0.57) | MMP12PARP1PDE3BPDE3ANR3C2 | |
| SCHEMBL16230037 | 0.80 | AHR (0.42) | PDE3BPDE3A | |
| SCHEMBL9953566 | 0.78 | AHR (0.42) | PDE3BPDE3APGRGAAPKM | |
| SCHEMBL13266843 | 0.76 | MMP12 (0.50) | MMP12PARP1PDE3BPDE3ANR3C2 | |
| SCHEMBL22421229 | 0.75 | PARP1 (0.52) | MMP12PARP1PDE3BPDE3ANR3C2 | |
| SCHEMBL421621 | 0.71 | CYP11B1 (0.47) | MMP12PARP1PDE3BPDE3AALDH1A1 | |
| SCHEMBL30284843 | 0.71 | CYP11B1 (0.47) | MMP12PARP1PDE3BPDE3AALDH1A1 | |
| SCHEMBL279594 | 0.68 | MMP12 (1.00) | MMP12PARP1ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL20627795 | 0.68 | BACE1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903991-B1 | ANTI-FIBROTIC PYRIDINONES | INTERMUNE INC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10544161-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10376497-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9675593-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9359379-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| WO-2015153683-A1 | ANTI-FIBROTIC PYRIDINONES | INTERMUNE, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | MMP1, COL1A1, COL2A1 | MMP12 49/4885PARP1 553/4885PDE3B 301/4885 |
| US-10544161-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | MMP12 49/4885PARP1 553/4885PDE3B 301/4885 |
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | MMP1, COL1A1, COL2A1 | MMP12 49/4885PARP1 553/4885PDE3B 301/4885 |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | MMP12 49/4885PARP1 553/4885PDE3B 301/4885 |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | MMP12 49/4885PARP1 553/4885PDE3B 301/4885 |
| US-10376497-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | MMP12 49/4885PARP1 553/4885PDE3B 301/4885 |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | MMP12 49/4885PARP1 553/4885PDE3B 301/4885 |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | MMP12 49/4885PARP1 553/4885PDE3B 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.